An earlier UK-wide study using primary care data from people with T2D showed a 31% reduction in HbA1c testing, a 20% reduction in new metformin prescribing and 5% reduction in new insulin prescribing between March and December 2020 compared with historical trends.13 Here we extend these observations by assessing the impact of the COVID-19 pandemic on a much wider range of health checks and a wider range of diabetes-related medication including agents that reduce cardiovascular risk. This evidence concerns the gene INS and type 2 diabetes mellitus.